2seventy bio, Inc. (TSVT)
(Delayed Data from NSDQ)
$4.09 USD
-0.11 (-2.62%)
Updated Jun 13, 2024 03:59 PM ET
After-Market: $4.10 +0.01 (0.24%) 7:58 PM ET
2-Buy of 5 2
F Value C Growth A Momentum D VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
TSVT 4.09 -0.11(-2.62%)
Will TSVT be a Portfolio Killer in June?
Zacks Investment Research is releasing its prediction for TSVT based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for TSVT
Bristol Myers (BMY) Gets FDA Nod for Breyanzi Label Expansion
2seventy bio, Inc. (TSVT) Reports Q1 Loss, Tops Revenue Estimates
TSVT: What are Zacks experts saying now?
Zacks Private Portfolio Services
CRISPR (CRSP) to Report Q1 Earnings: What's in the Cards?
Regeneron (REGN) Q1 Earnings, Sales Miss on Lower Eylea Sales
Will Alector (ALEC) Report Negative Q1 Earnings? What You Should Know
Other News for TSVT
2seventy bio’s Board Elections and Financial Oversight Update
What You Missed On Wall Street This Morning
Goldman cuts 2seventy bio to neutral, cites competition concerns
Analysts Offer Insights on Healthcare Companies: 2seventy bio (TSVT), Insmed (INSM) and Relay Therapeutics (RLAY)
2seventy Bio just downgraded at Goldman Sachs, here's why